Want to see CLBT full AI Analyst Report?
Top Page
Cellebrite DI
(NASDAQ:CLBT)
Select Model
Select Model
Rating:78Outperform
Price Target:
$19.00
▲(33.61% Upside)
Action:Reiterated
Date:06/02/26
The score is driven primarily by strong financial quality (high margins, robust free cash flow, low leverage) and a positive earnings-call setup (guidance for ARR acceleration plus strategic catalysts like AI products and FedRAMP). Offsetting factors are a rich valuation (P/E ~54) and technical indicators that are strong but near overbought, alongside the fundamental risk of slowing recent revenue growth versus prior periods.
Positive Factors
High margins and strong free cash flow
Cellebrite’s very high gross margin and sizable trailing‑twelve‑month free cash flow support durable profitability and internal reinvestment. Strong cash conversion (~0.92 FCF to earnings) and operating cash buffer provide flexibility for R&D, product launches, and disciplined M&A without stressing the balance sheet.
Negative Factors
Recent slowdown in reported revenue growth
A marked deceleration in trailing revenue growth signals potential saturation, timing issues, or mix shifts that could hinder multi‑period topline expansion. Sustained recovery depends on converting new products and regions into recurring revenue, so this trend raises medium‑term execution demands on sales and product teams.
Read all positive and negative factors
Positive Factors
Negative Factors
High margins and strong free cash flow
Cellebrite’s very high gross margin and sizable trailing‑twelve‑month free cash flow support durable profitability and internal reinvestment. Strong cash conversion (~0.92 FCF to earnings) and operating cash buffer provide flexibility for R&D, product launches, and disciplined M&A without stressing the balance sheet.
Read all positive factors
Cellebrite DI Key Performance Indicators (KPIs)
Any
Revenue by Geography
Maps where sales are coming from across regions, indicating dependence on particular markets, exposure to geopolitical or regulatory risk, and where expansion or slowdown might materially affect overall growth.
Maps where sales are coming from across regions, indicating dependence on particular markets, exposure to geopolitical or regulatory risk, and where expansion or slowdown might materially affect overall growth.
Data provided by:
The Fly
The FlyCellebrite DI (CLBT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.00B
Dividend YieldN/A
Average Volume (3M)1.82M
Price to Earnings (P/E)52.2
Beta (1Y)0.87
Revenue Growth18.43%
EPS GrowthN/A
CountryUS
Employees1,285
SectorTechnology
Sector Strength88
IndustrySoftware - Infrastructure
Share Statistics
EPS (TTM)0.29
Shares Outstanding249,439,820
10 Day Avg. Volume1,393,342
30 Day Avg. Volume1,818,489
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)9.41
Price to Sales (P/S)9.58
P/FCF Ratio29.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.25Price Target Upside28.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.33
Revenue Forecast (FY)$567.97M
Cellebrite DI Business Overview & Revenue Model
Company Description
Cellebrite DI Ltd. delivers specialized digital intelligence solutions crafted for legally authorized investigations. Their comprehensive DI platform enables users to efficiently gather, scrutinize, interpret, and oversee digital information throu...
How the Company Makes Money
Cellebrite makes money primarily by selling access to its digital intelligence software and related services to customers such as public-sector agencies and enterprises. Key revenue streams include: (1) Software subscriptions/licenses: recurring r...
Cellebrite DI Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Neutral
The call was mixed. The company reported strong underlying metrics (ARR +21%, revenue +16%, high gross margin and improved EBITDA guidance), meaningful new-product traction (Genesis, Guardian, Advanced Unlocks) and healthy cash/FCF. However, execution and timing issues on several large, cloud/AI deals—driven by new procurement and foreign-entity requirements and lower-than-expected ARR uplift from Insights conversions—led management to lower full-year ARR guidance and caution on near-term growth. Management emphasized improved sales rigor, tighter forecasting, and disciplined cost management, suggesting the company is addressing issues while maintaining confidence in long-term opportunity.Positive Updates
ARR Growth
ARR increased 21% year-over-year to $508 million (Q2 2026), reflecting ongoing subscription momentum despite quarterly execution shortfalls.
Negative Updates
Missed ARR Guidance and Execution Shortfall
The company missed the bottom end of its Q2 ARR guidance and acknowledged it 'did not deliver the ARR and revenue performance expected' due to timing slips on several large transactions.
Read all updates
Q2-2026 Updates
Positive
Negative
ARR Growth
ARR increased 21% year-over-year to $508 million (Q2 2026), reflecting ongoing subscription momentum despite quarterly execution shortfalls.
Read all positive updates
Company Guidance
Management lowered full‑year ARR to $550–560M (≈$15M midpoint reduction; ARR growth 14–16%) and trimmed full‑year revenue to $555–561M (growth ~17–18%) while raising adjusted EBITDA to $153–159M (≈28% margin) and reiterating a target ~30% free cash flow margin for 2026; Q3 guidance is ARR $524–528M (net new ARR $16–20M), revenue $145–148M and adjusted EBITDA $42–45M (29–30% margin). For context, Q2 ARR was $508M (+21%), revenue $131M (+16%), subscription revenue $119.5M (91% of revenue), gross profit $112M (86% margin), adjusted EBITDA $31.8M (24% margin), cash/investments $546M and TTM free cash flow $144.2M (28% margin); growth products drove 25% of the $15M sequential ARR increase, Genesis contributed ≈$400k ARR in late June, Insights reached ~65% of the installed base but is now expected to add only mid‑single digits to ARR, Defense & Intelligence ARR grew 25%, regional ARR mix was Americas 53%/EMEA 34%/APAC 13% (growth rates 19%/23%/29%), Corellium is expected to contribute 1–2 points, Guardian/Pathfinder/Genesis the lower end of mid‑single digits, management expects ~3 points of FX headwind and at least a 1‑point improvement in gross revenue retention.Cellebrite DI Financial Statement Overview
Summary
Income Statement
77
Positive
Balance Sheet
88
Very Positive
Cash Flow
83
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 496.43M | 475.68M | 401.20M | 325.11M | 270.65M | 246.25M |
| Gross Profit | 416.32M | 400.50M | 338.61M | 271.88M | 219.91M | 203.69M |
| EBITDA | 127.62M | 103.07M | -265.35M | -65.41M | 130.10M | 89.47M |
| Net Income | 71.86M | 78.33M | -283.01M | -81.10M | 120.81M | 71.40M |
Balance Sheet | ||||||
| Total Assets | 952.29M | 938.85M | 690.57M | 532.88M | 403.29M | 339.78M |
| Cash, Cash Equivalents and Short-Term Investments | 429.07M | 437.05M | 447.22M | 302.92M | 183.62M | 181.56M |
| Total Debt | 22.80M | 22.67M | 10.97M | 14.13M | 15.36M | 0.00 |
| Total Liabilities | 441.75M | 454.53M | 354.55M | 498.67M | 329.43M | 413.13M |
| Stockholders Equity | 510.54M | 484.32M | 336.02M | 34.21M | 73.86M | -73.35M |
Cash Flow | ||||||
| Free Cash Flow | 154.04M | 155.73M | 121.56M | 94.14M | 11.49M | 27.94M |
| Operating Cash Flow | 167.97M | 168.96M | 132.17M | 102.06M | 20.58M | 36.05M |
| Investing Cash Flow | -155.32M | -268.25M | -149.47M | -22.54M | -91.23M | 45.23M |
| Financing Cash Flow | 29.53M | 29.64M | 20.65M | 21.77M | 13.97M | -68.40M |
Cellebrite DI Technical Analysis
Positive
14.22
Price Trends
14.61
Positive
13.94
Positive
15.17
Positive
Market Momentum
0.27
Negative
50.95
Neutral
67.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLBT, the sentiment is Positive. The current price of 14.22 is below the 20-day moving average (MA) of 15.14, below the 50-day MA of 14.61, and below the 200-day MA of 15.17, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 50.95 is Neutral, neither overbought nor oversold. The STOCH value of 67.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLBT.
Cellebrite DI Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $4.00B | 52.21 | 15.53% | ― | 18.43% | ― | |
72 Outperform | $1.11B | 17.45 | 6.22% | 6.94% | 5.43% | 208.11% | |
71 Outperform | $1.76B | 19.75 | 15.04% | 0.67% | 12.36% | -28.24% | |
65 Neutral | $1.23B | 74.08 | 5.05% | ― | 9.98% | 18.53% | |
62 Neutral | $4.84B | -34.37 | -26.91% | ― | 15.86% | -33.39% | |
62 Neutral | $4.17B | 591.05 | 2.41% | ― | 9.93% | ― | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
* Technology Sector Average
CLBT
Cellebrite DI
15.25
-0.04
-0.26%
RDWR
Radware
29.10
4.86
20.05%
EVTC
Evertec
30.41
-6.32
-17.21%
VRNS
Varonis Systems
41.93
-15.02
-26.37%
TENB
Tenable Holdings
37.00
7.90
27.15%
TUYA
Tuya
1.79
-0.52
-22.44%
Cellebrite DI Corporate Events
Cellebrite Posts Strong Q1 2026 Growth, Expands AI and Drone Forensics Portfolio
May 14, 2026
On May 14, 2026, Cellebrite reported first-quarter 2026 results showing revenue of $128.3 million, up 19% year over year, with subscription revenue rising 23% to $117.9 million and annual recurring revenue climbing 21% to $493 million. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.